AU753573B2 - Nanoparticles comprising polyisobutylcyanoacrylate and cyclodextrins - Google Patents

Nanoparticles comprising polyisobutylcyanoacrylate and cyclodextrins Download PDF

Info

Publication number
AU753573B2
AU753573B2 AU26287/99A AU2628799A AU753573B2 AU 753573 B2 AU753573 B2 AU 753573B2 AU 26287/99 A AU26287/99 A AU 26287/99A AU 2628799 A AU2628799 A AU 2628799A AU 753573 B2 AU753573 B2 AU 753573B2
Authority
AU
Australia
Prior art keywords
nanoparticles
active ingredient
nanoparticles according
cyclic oligosaccharide
speci
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU26287/99A
Other languages
English (en)
Other versions
AU2628799A (en
Inventor
Patrick Couvreur
Dominique Duchene
Airton Monza Da Silveira
Gilles Ponchel
Francis Puisieux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioalliance Pharma SA
Original Assignee
Bioalliance Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioalliance Pharma SA filed Critical Bioalliance Pharma SA
Publication of AU2628799A publication Critical patent/AU2628799A/en
Application granted granted Critical
Publication of AU753573B2 publication Critical patent/AU753573B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU26287/99A 1998-02-27 1999-02-24 Nanoparticles comprising polyisobutylcyanoacrylate and cyclodextrins Ceased AU753573B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR98/02429 1998-02-27
FR9802429A FR2775435B1 (fr) 1998-02-27 1998-02-27 Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs
PCT/FR1999/000418 WO1999043359A1 (fr) 1998-02-27 1999-02-24 Nanoparticules comprenant polyisobutylcyanoacrylate et cyclodextrines

Publications (2)

Publication Number Publication Date
AU2628799A AU2628799A (en) 1999-09-15
AU753573B2 true AU753573B2 (en) 2002-10-24

Family

ID=9523473

Family Applications (1)

Application Number Title Priority Date Filing Date
AU26287/99A Ceased AU753573B2 (en) 1998-02-27 1999-02-24 Nanoparticles comprising polyisobutylcyanoacrylate and cyclodextrins

Country Status (12)

Country Link
US (1) US6881421B1 (cg-RX-API-DMAC7.html)
EP (1) EP1056477B1 (cg-RX-API-DMAC7.html)
JP (1) JP4651192B2 (cg-RX-API-DMAC7.html)
AT (1) ATE311906T1 (cg-RX-API-DMAC7.html)
AU (1) AU753573B2 (cg-RX-API-DMAC7.html)
CA (1) CA2320928C (cg-RX-API-DMAC7.html)
DE (1) DE69928776T2 (cg-RX-API-DMAC7.html)
DK (1) DK1056477T3 (cg-RX-API-DMAC7.html)
ES (1) ES2255246T3 (cg-RX-API-DMAC7.html)
FR (1) FR2775435B1 (cg-RX-API-DMAC7.html)
IL (2) IL137882A0 (cg-RX-API-DMAC7.html)
WO (1) WO1999043359A1 (cg-RX-API-DMAC7.html)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582713B2 (en) 2000-04-06 2003-06-24 Univ. Of Colorado - Colorado Springs Compositions and methods for promoting wound healing
FR2808691B1 (fr) * 2000-05-12 2005-06-24 Coletica Cyclodextrines substituees preferentiellement sur leur face primaire par des fonctions acide ou amine
FR2816949B1 (fr) * 2000-11-17 2003-11-28 Centre Nat Rech Scient Copolymere a structure sequencee compose d'un segment saccharidique lie a au moins un segment hydrophobe bioerodable, et particules correspondantes
US6890703B2 (en) 2002-03-06 2005-05-10 International Business Machines Corporation Preparation of crosslinked particles from polymers having activatible crosslinking groups
ATE539737T1 (de) * 2002-04-12 2012-01-15 Alkermes Pharma Ireland Ltd Nanopartikuläre megestrol- formulierungen
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
FR2841137B1 (fr) * 2002-06-20 2004-08-13 Bioalliance Pharma Systeme de vectorisation comprenant des nanoparticules de taille homogene d'au moins un polymere et d'au moins un polysaccharide charge positivement
WO2004022100A1 (en) * 2002-08-15 2004-03-18 Yunqing Liu Soild nano pharmaceutical formulation and preparation method thereof
US20050051968A1 (en) * 2002-11-13 2005-03-10 Froesel David William Washer toss game
US8128954B2 (en) 2004-06-07 2012-03-06 California Institute Of Technology Biodegradable drug-polymer delivery system
FR2872703B1 (fr) * 2004-07-07 2006-10-06 Ethypharm Sa Nanoparticules polymeriques composites
JP2008513363A (ja) * 2004-09-14 2008-05-01 ナノデル テクノロジーズ ゲーエムベーハー ナノ粒子を含む送達媒体
CA2580529A1 (en) * 2004-10-01 2006-04-13 Eisai R & D Management Co., Ltd. Fine particle-containing composition and manufacturing method therefor
WO2007047253A2 (en) * 2005-10-11 2007-04-26 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
KR100726720B1 (ko) 2005-12-26 2007-06-11 코스맥스 주식회사 수난용성 활성물질을 하이드록시알킬화 사이클로덱스트린과리포좀으로 이중 안정화 시킨 나노캡슐 리포좀 조성물
AU2007265452A1 (en) * 2006-06-26 2008-01-03 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
US8679539B2 (en) * 2007-01-31 2014-03-25 Tong Shen Enterprise Co., Ltd. Drug-loaded poly (alkyl-cyanoacrylate) nanoparticles and process for the preparation thereof
JP5224313B2 (ja) * 2007-02-27 2013-07-03 公立大学法人横浜市立大学 プラスミド送達用粒子
ES2310122B1 (es) * 2007-04-20 2009-10-30 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones.
US9132296B2 (en) 2007-05-17 2015-09-15 Ag Essence Antimicrobial solution and methods of making and using the same
US8729121B2 (en) * 2007-06-25 2014-05-20 Adhezion Biomedical, Llc Curing accelerator and method of making
EP2211727B1 (en) * 2007-11-14 2014-03-12 Adhezion Biomedical, LLC Cyanoacrylate tissue adhesives
CN101959523A (zh) * 2007-12-27 2011-01-26 公立大学法人横浜市立大学 革兰氏阳性细菌用抗菌剂
US8293838B2 (en) * 2008-06-20 2012-10-23 Adhezion Biomedical, Llc Stable and sterile tissue adhesive composition with a controlled high viscosity
US8198344B2 (en) 2008-06-20 2012-06-12 Adhezion Biomedical, Llc Method of preparing adhesive compositions for medical use: single additive as both the thickening agent and the accelerator
US20110117047A1 (en) 2008-06-23 2011-05-19 Adhezion Biomedical, Llc Cyanoacrylate tissue adhesives with desirable permeability and tensile strength
EP2153821A1 (en) 2008-08-06 2010-02-17 BioAlliance Pharma Oral formulations of camptothecin derivatives
US8609128B2 (en) * 2008-10-31 2013-12-17 Adhezion Biomedical, Llc Cyanoacrylate-based liquid microbial sealant drape
US9254133B2 (en) 2008-10-31 2016-02-09 Adhezion Biomedical, Llc Sterilized liquid compositions of cyanoacrylate monomer mixtures
US8652510B2 (en) 2008-10-31 2014-02-18 Adhezion Biomedical, Llc Sterilized liquid compositions of cyanoacrylate monomer mixtures
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
WO2010138193A2 (en) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
KR101522918B1 (ko) 2009-05-29 2015-05-27 사이덱스 파마슈티칼스, 인크. 사이클로덱스트린 유도체를 포함하는 주사용 멜팔란 조성물 및 이의 제조 및 사용 방법
US9309019B2 (en) 2010-05-21 2016-04-12 Adhezion Biomedical, Llc Low dose gamma sterilization of liquid adhesives
CN107029223A (zh) 2010-05-26 2017-08-11 西莱克塔生物科技公司 合成纳米载体联合疫苗
FR2968662B1 (fr) 2010-12-10 2013-11-22 Roussy Inst Gustave Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation
ES2424476T3 (es) 2011-03-31 2013-10-02 Bioalliance Pharma Nanopartículas cargadas con fármaco antitumoral quimioterápico
JP5938836B2 (ja) 2011-03-31 2016-06-22 株式会社ナノカム 高次構造体が示す抗細胞効果の新規調整技法
CN107320734A (zh) 2011-04-29 2017-11-07 西莱克塔生物科技公司 从合成纳米载体中控制释放免疫抑制剂
JP2014521687A (ja) 2011-07-29 2014-08-28 セレクタ バイオサイエンシーズ インコーポレーテッド 体液性および細胞傷害性tリンパ球(ctl)免疫応答を生成する合成ナノキャリア
US10988618B2 (en) 2011-09-23 2021-04-27 Dystar Hilton Davis Corp. Self-assembled nano-structured particle and methods for preparing
MX367283B (es) 2011-09-23 2019-08-13 Emerald Hilton Davis Lcc Particula nanoestructurada autoensamblada y metodo para su preparacion.
JP6192543B2 (ja) 2012-01-19 2017-09-06 昇一 城武 植物病原細菌用抗菌剤
CN102579402B (zh) * 2012-03-26 2013-07-03 山东大学 一种负载紫杉醇的囊泡的制备方法
US11547116B2 (en) 2012-12-12 2023-01-10 William Wingfield Metal oxide compounds and infusion into polymer compounds
CN105307641A (zh) 2013-05-03 2016-02-03 西莱克塔生物科技公司 用于降低不期望体液免疫应答的给药组合
JP6533213B2 (ja) * 2014-02-27 2019-06-19 昇一 城武 抗ウイルス剤
US9421297B2 (en) 2014-04-02 2016-08-23 Adhezion Biomedical, Llc Sterilized compositions of cyanoacrylate monomers and naphthoquinone 2,3-oxides
WO2017046037A1 (en) 2015-09-14 2017-03-23 Onxeo Nanoparticles loaded with active ingredients, their process of preparation and their uses
CA3015241A1 (en) 2016-02-22 2017-08-31 Onxeo Combination therapies comprising immuno-oncology agents and belinostat
US11491114B2 (en) 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
EP4599848A3 (en) 2017-03-11 2025-12-03 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
ES2994451T3 (en) 2017-04-20 2025-01-24 Atyr Pharma Inc Compositions for treating lung inflammation
WO2019195770A1 (en) 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
IL317993B2 (en) 2018-07-03 2025-11-01 Gilead Sciences Inc Antibodies directed against HIV gp120 and methods of use
AU2019312366B2 (en) 2018-07-26 2025-08-14 Atyr Pharma, Inc. Compositions and methods for treating NRP2-associated diseases
US12553041B2 (en) 2019-06-04 2026-02-17 Cartesian Therapeutics Inc. Formulations and doses of pegylated uricase
CN114245807B (zh) 2019-06-25 2025-05-02 吉利德科学公司 Flt3l-fc融合蛋白和使用方法
AU2020315598B2 (en) 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
HRP20241379T1 (hr) 2019-09-30 2024-12-20 Gilead Sciences, Inc. Cjepiva za hbv i postupci za liječenje hbv
AU2020358854B2 (en) 2019-10-03 2026-08-13 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
CA3128035A1 (en) 2020-08-13 2022-02-13 Bioasis Technologies, Inc. Combination therapies for delivery across the blood brain barrier
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CA3259040A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. HIV Immunogenic Polypeptides and Vaccines and Their Uses
US20260209367A1 (en) 2024-11-22 2026-07-23 Gilead Sciences, Inc. SINGLE IMMUNOGLOBULIN DOMAIN BISPECIFIC ANTIBODIES AGAINST IL 10R alpha AND beta SUBUNITS AND METHODS OF USE

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641515A (en) * 1995-04-04 1997-06-24 Elan Corporation, Plc Controlled release biodegradable nanoparticles containing insulin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504408B1 (fr) * 1981-04-24 1986-02-14 Couvreur Patrick Procede de preparation de particules submicroscopiques, particules ainsi obtenues et compositions pharmaceutiques les contenant
US5246611A (en) * 1990-05-09 1993-09-21 The Procter & Gamble Company Non-destructive carriers for cyclodextrin complexes
WO1992004916A2 (en) * 1990-09-14 1992-04-02 St. George's Enterprises Limited Particulate agents
FR2692168B1 (fr) * 1992-06-16 1995-03-24 Centre Nat Rech Scient Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères.
JP4619457B2 (ja) * 1993-11-18 2011-01-26 シルテックス、メディカル、リミテッド 徐放性製剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641515A (en) * 1995-04-04 1997-06-24 Elan Corporation, Plc Controlled release biodegradable nanoparticles containing insulin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EGEA ET AL. FARMACO. 1994. 49: 211-17 *

Also Published As

Publication number Publication date
FR2775435B1 (fr) 2000-05-26
FR2775435A1 (fr) 1999-09-03
DE69928776T2 (de) 2006-09-07
EP1056477A1 (fr) 2000-12-06
DK1056477T3 (da) 2006-04-18
EP1056477B1 (fr) 2005-12-07
ES2255246T3 (es) 2006-06-16
CA2320928C (fr) 2009-12-15
ATE311906T1 (de) 2005-12-15
US6881421B1 (en) 2005-04-19
IL137882A (en) 2006-12-31
JP4651192B2 (ja) 2011-03-16
AU2628799A (en) 1999-09-15
IL137882A0 (en) 2001-10-31
CA2320928A1 (fr) 1999-09-02
JP2002504526A (ja) 2002-02-12
DE69928776D1 (de) 2006-01-12
WO1999043359A1 (fr) 1999-09-02

Similar Documents

Publication Publication Date Title
US6881421B1 (en) Nanoparticles comprising at least one polymer and at least one compound able to complex one or more active ingredients
JP2002504526A5 (cg-RX-API-DMAC7.html)
Vandervoort et al. Preparation and evaluation of drug-loaded gelatin nanoparticles for topical ophthalmic use
Ayumi et al. Polymeric nanoparticles for topical delivery of alpha and beta arbutin: preparation and characterization
Govender et al. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug
Duchêne et al. Cyclodextrins in targeting: application to nanoparticles
Khalil et al. Preparation and evaluation of warfarin-β-cyclodextrin loaded chitosan nanoparticles for transdermal delivery
Zafar et al. Cyclodextrin containing biodegradable particles: from preparation to drug delivery applications
Duchêne et al. Cyclodextrins and carrier systems
Cavalli et al. Enhanced antiviral activity of Acyclovir loaded into β-cyclodextrin-poly (4-acryloylmorpholine) conjugate nanoparticles
Trapani et al. The potential of glycol chitosan nanoparticles as carrier for low water soluble drugs
US7682635B2 (en) Aqueous dispersions of nanometric or micrometric particles for encapsulating chemical compounds
Shahgaldian et al. A study of the freeze-drying conditions of calixarene based solid lipid nanoparticles
Nehilla et al. Purified and surfactant-free coenzyme Q10-loaded biodegradable nanoparticles
Filipović-Grčić et al. Chitosan microspheres with hydrocortisone and hydrocortisone–hydroxypropyl-β-cyclodextrin inclusion complex
Perret et al. Design, synthesis, and in vitro evaluation of new amphiphilic cyclodextrin-based nanoparticles for the incorporation and controlled release of acyclovir
Memişoğlu et al. Non-surfactant nanospheres of progesterone inclusion complexes with amphiphilic β-cyclodextrins
Pariot et al. Cross-linked β-cyclodextrin microcapsules: preparation and properties
Pariot et al. Cross-linked β-cyclodextrin microcapsules. II. Retarding effect on drug release through semi-permeable membranes
Yuan et al. Self-assembled low molecular weight chitosan-based cationic micelle for improved water solubility, stability and sustained release of α-tocopherol
Balakrishanan et al. Size-controlled synthesis of biodegradable nanocarriers for targeted and controlled cancer drug delivery using salting out cation
Ibrahim et al. Biosynthesized poly (3-hydroxybutyrate-co-3-hydroxyvalerate) as biocompatible microcapsules with extended release for busulfan and montelukast
EP1440114A1 (fr) Materiau compose d'au moins un polymere biodegradable et de cyclodextrines
Dollo et al. Inclusion complexation of amide-typed local anaesthetics with β-cyclodextrin and its derivatives. ii. evaluation of affinity constants and in vitro transfer rate constants
Arias et al. Engineering of an antitumor (core/shell) magnetic nanoformulation based on the chemotherapy agent ftorafur

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)